Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5302 | 0.86 | GPR139 (0.39) | PIK3CDGPR139CTSAL3MBTL1PDE2A | |
| SCHEMBL863999 | 0.85 | GPR139 (0.38) | PIK3CDGPR139CTSAL3MBTL1USP9X | |
| SCHEMBL864285 | 0.82 | MAT2A (0.39) | PIK3CDGPR139CTSAL3MBTL1PDE2A | |
| SCHEMBL863538 | 0.82 | KCNJ5 (0.42) | PIK3CDGPR139CTSA | |
| SCHEMBL864320 | 0.82 | KCNJ5 (0.42) | PIK3CDGPR139CTSA | |
| SCHEMBL865348 | 0.82 | KDM4E (0.45) | PIK3CDGPR139CTSA | |
| SCHEMBL863539 | 0.82 | KCNJ5 (0.42) | PIK3CDGPR139CTSA | |
| SCHEMBL865362 | 0.80 | PIP4K2C (0.42) | PIK3CD | |
| SCHEMBL864954 | 0.79 | PIK3CD (0.46) | PIK3CD | |
| SCHEMBL863898 | 0.79 | USP9X (0.36) | PIK3CDGPR139CTSAL3MBTL1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885GPR139 2123/4885CTSA 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.